Santhera Pharmaceuticals Holding AG has raised CHF 23.5 million (€20.82 million) in a share placement to complete the acquisition of rights to vamorolone, a synthetic glucocorticoid corticosteroid which is being developed for Duchenne muscular dystrophy (DMD).
